| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Second Department of Surgery and Department of Radiology, Chiba University School of Medicine, Chiba, Japan
Correspondence: For correspondence or reprints contact: Toru Fukunaga, MD, Second Department of Surgery, Chiba University Schoolof Medicine, 1-8-1 Inohana, Chuo-ku Chiba, 260, Japan.
ABSTRACT
To evaluate glucose metabolism in esophageal cancer, 48 patients were studied using PET with 18F-2-fluoro-2-deoxy-D-glucose (FDG). Methods: After transmission scans were obtained, 18F-FDG (148 MBq) was administered intravenously. In 11 patients, a dynamic study was performed to evaluate glucose metabolism. Using the changes of radioactivity in both plasma and tumor, rate constants (kl-k4) defined in the metabolic model for 18F-FDG were calculated. In 48 patients, static PET scans of the tumor (5-mins cans) were obtained 60 min after administration. Fluorine-18-FDG activity within each tumor was corrected for physical decay and normalized by dose administration and patient weight to produce a standardized uptake value (SUV). Results: Both the k3 value(n = 11) reflecting hexokinase activity and SUV (n = 13) were well correlated with hexokinase activity from the resected specimen (p < 0.05). Forty-seven of 48 patients before treatment revealed SUV greater than 2.0, but 10 normal control subjects and 1 esophageal benign tumor revealed less than 2.0 (accuracy rate 98.3%). Although clinicopathological findings did not correlate with SUV, except for two patients with carcinosarcoma, 23 patients with an SUV greater than 7.0 had a poor prognosis compared with 25 patients with SUVs lessthan 7.0. ConclusIon: These findings suggest that 18F-FDG PET may be useful in distinguishing malignant tumors from benign lesions and in the preoperative evaluation of the prognostic factor.
Key Words: PET • fluorine-18-fluorodeoxyglucose • esophageal cancer • prognosis
This article has been cited by other articles:
|
|
 |
|
  L. de Geus-Oei, B Wiering, P. Krabbe, T. Ruers, C. Punt, and W. Oyen FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma Ann. Onc., November 1, 2006; 17(11): 1650 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. van Westreenen, J. T. M. Plukker, D. C. P. Cobben, C. J. M. Verhoogt, H. Groen, and P. L. Jager Prognostic Value of the Standardized Uptake Value in Esophageal Cancer Am. J. Roentgenol., August 1, 2005; 185(2): 436 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schoder, A. Noy, M. Gonen, L. Weng, D. Green, Y. E. Erdi, S. M. Larson, and H. W.D. Yeung Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., July 20, 2005; 23(21): 4643 - 4651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tseng, L. K. Dunnwald, E. K. Schubert, J. M. Link, S. Minoshima, M. Muzi, and D. A. Mankoff 18F-FDG Kinetics in Locally Advanced Breast Cancer: Correlation with Tumor Blood Flow and Changes in Response to Neoadjuvant Chemotherapy J. Nucl. Med., November 1, 2004; 45(11): 1829 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Choi, H.-J. Jang, Y. M. Shim, K. Kim, K. S. Lee, K.-H. Lee, Y. Choi, Y. S. Choe, and B.-T. Kim 18F-FDG PET in Patients with Esophageal Squamous Cell Carcinoma Undergoing Curative Surgery: Prognostic Implications J. Nucl. Med., November 1, 2004; 45(11): 1843 - 1850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A.M. Heeren, P. L. Jager, F. Bongaerts, H. van Dullemen, W. Sluiter, and J. Th.M. Plukker Detection of Distant Metastases in Esophageal Cancer with 18F-FDG PET J. Nucl. Med., June 1, 2004; 45(6): 980 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yoshioka, K. Yamaguchi, K. Kubota, T. Saginoya, T. Yamazaki, T. Ido, G. Yamaura, H. Takahashi, H. Fukuda, and R. Kanamaru Evaluation of 18F-FDG PET in Patients with Advanced, Metastatic, or Recurrent Gastric Cancer J. Nucl. Med., May 1, 2003; 44(5): 690 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Himeno, S. Yasuda, H. Shimada, T. Tajima, and H. Makuuchi Evaluation of Esophageal Cancer by Positron Emission Tomography Jpn. J. Clin. Oncol., September 1, 2002; 32(9): 340 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Higashi, T. Saga, Y. Nakamoto, T. Ishimori, M. H. Mamede, M. Wada, R. Doi, R. Hosotani, M. Imamura, and J. Konishi Relationship Between Retention Index in Dual-Phase 18F-FDG PET, and Hexokinase-II and Glucose Transporter-1 Expression in Pancreatic Cancer J. Nucl. Med., February 1, 2002; 43(2): 173 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Toita, K. Ogawa, G. Adachi, Y. Kakinohana, Y. Nishikuramori, S. Iraha, T. Utsunomiya, and S. Murayama Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Thoracic Esophagus: Feasibility and Outcome of Large Regional Field and High-dose External Beam Boost Irradiation Jpn. J. Clin. Oncol., August 1, 2001; 31(8): 375 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Flamen, A. Lerut, E. Van Cutsem, J. P. Cambier, A. Maes, W. De Wever, M. Peeters, P. De Leyn, D. Van Raemdonck, and L. Mortelmans The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer J. Thorac. Cardiovasc. Surg., December 1, 2000; 120(6): 1085 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Flamen, A. Lerut, E. Van Cutsem, W. De Wever, M. Peeters, S. Stroobants, P. Dupont, G. Bormans, M. Hiele, P. De Leyn, et al. Utility of Positron Emission Tomography for the Staging of Patients With Potentially Operable Esophageal Carcinoma J. Clin. Oncol., September 18, 2000; 18(18): 3202 - 3210. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
